Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Chronic Lymphocytic Leukemia

Breast Cancer

Gastrointestinal Cancer

Chronic Lymphocytic Leukemia

FDA Grants Priority Review to Ibrutinib Plus Obinutuzumab in Frontline CLL

The FDA has granted a priority designation to a supplemental new drug application for ibrutinib for use in combination with obinutuzumab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More >>

Combination Trials Signal Next Wave of Treatment for CLL

Novel Agents and Approaches Continue to Advance Through CLL Pipeline

BTK Inhibitor Success Puts Focus on Resistance Mechanisms

CLL Landscape Continues to Expand With Addition of Venetoclax

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

View More Stories >>

View Conference Coverage

2018 State of the Science Summit on Hematologic Malignancies in Clayton

State of the Science Summit on GI Cancers in Newport Beach

2018 ESMO Congress

2018 State of the Science Summit on Hematologic Malignancies in Cleveland

2018 Lynn Sage Breast Cancer Symposium

Dr. Arora Discusses the Role of MRD Status in CLL

Dr. Hill on Recent Advances in Treatment of CLL

Dr. Shadman on the Future of Venetoclax in CLL

Dr. Seymour on Shifting Standards of Care in CLL

Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular Lymphoma

Dr. Pinilla-Ibarz on the Impact of Venetoclax in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Evaluating CAR T-Cell Therapy Use

The Role of Transplant and Future of CLL

Other Promising Strategies in CLL

Maintenance and Frontline Therapy in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

The Evolving Treatment Landscape of CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

Relapsed/Refractory CLL: Evaluating Other Novel Agents

$Novel Approaches to Treating Relapsed/Refractory CLL$

Novel Approaches to Treating Relapsed/Refractory CLL

$Continuing Therapy in Relapsed/Refractory CLL$

$Evaluating Pharmacologic Agents in Relapsed/Refractory CLL$

CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

$Approaching Therapy for Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Other Promising Strategies in CLL

This expert panel discussion led by William Wierda, MD, focuses on promising strategies available for the treatment of chronic lymphocytic leukemia. Dr. Wierda is joined in this discussion by Steven Coutre, MD; Matthew S. Davids, MD, MMSc; Nicole Lamanna, MD; and Shuo Ma, MD, PhD.

View Now

The Use of Novel PI3K Inhibitors in CLL

In this segment William Wierda, MD, PhD, leads a panel discussion regarding the use of novel PI3K inhibitors in chronic lymphocytic leukemia.

View Now

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

OncLive News Network On Location: 2018 ESMO Congress